Skip to main content
Clinical Trials/NCT02812134
NCT02812134
Unknown
Not Applicable

Impact of Oral Phosphorus Supplements on the 6-month Change in FGF23 Levels in Anorexic Adolescents Suffering From Undernutrition.

Centre Hospitalier Universitaire, Amiens1 site in 1 country30 target enrollmentJune 2015
ConditionsMalnutrition

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Malnutrition
Sponsor
Centre Hospitalier Universitaire, Amiens
Enrollment
30
Locations
1
Primary Endpoint
FGF23
Last Updated
7 years ago

Overview

Brief Summary

Fibroblast growth factor 23 (FGF23) is a recently discovered phosphaturic hormone produced by osteocytes. It is involved in phosphate-calcium metabolism (via its phosphaturic action and inhibition of 1,25-OH vitamin D).

There are no published studies on the role of FGF23 in undernourished anorexic adolescents taking oral phosphorus supplements.

Registry
clinicaltrials.gov
Start Date
June 2015
End Date
August 2018
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adolescents aged from 11 to 17
  • Follow-up or hospitalisation for anorexia
  • Overt undernutrition (clinical signs of undernutrition, body mass index and the Waterlow index)
  • Social security coverage

Exclusion Criteria

  • Known pre-existing renal disorders
  • Known constitutional disorders of phosphate-calcium metabolism
  • Adult patients, legal guardianship, incarceration

Outcomes

Primary Outcomes

FGF23

Time Frame: at inclusion and then once a month for 6 months.

Change in the FGF23 level (U/ml) with regard to the exogenous phosphorus intake (doses of Phosphoneuros®, expressed in mg/kg/day)

Study Sites (1)

Loading locations...

Similar Trials